Telix Pharmaceuticals develops and commercializes radiopharmaceuticals for cancer imaging and therapy (theranostics). Its lead approved products include Illuccix, a PSMA-targeted imaging agent used in prostate cancer diagnosis and staging. The pipeline targets urologic, neuro-oncology, and other solid tumors, supported by a growing global manufacturing and distribution network for radioactive doses.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 108.9 | — | -70.8 | — |
| 2023 | 333 | 205.7% | 4.2 | — |
| 2024 | 516.5 | 55.1% | 33.7 | 700.5% |
| 2025 | 803.8 | 55.6% | -7.1 | -121.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Academy Sports and Outdoors, Inc. (ASO), Legend Biotech Corporation (LEGN), Wingstop Inc. (WING), Freshworks Inc. (FRSH), Universal Display Corporation (OLED), iRhythm Holdings, Inc. (IRTC)